American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (986)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (940)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1255)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (311)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (62)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5172)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outpatient vs inpatient HiDA consolidation for AML: The MSKCC experience
    Meeting Abstract

    Boussi, L.; Burton, H.; Derkach, A.; Nemirovsky, D.; Ciervo, J.; Tallman, M. S.; Stein, E. M.; Cai, S.
    Blood (2024)

    Fulltext@MSK | Save
  • Addition of monoclonal protein to MALT-IPI improved identification of MALT patients at high risk of progression with current first-line therapies
    Meeting Abstract

    Epperla, N.; Grover, N.; Torka, P.; Karmali, R.; Annunzio, K.; Watkins, M. P.; Anampa--Guzmán, A. C.; Reves, H.; Tavakkoli, M.; Christian, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Development of CAR T cells targeting U5 snRNP200 for the treatment of acute myeloid and B-lymphoid leukemias
    Meeting Abstract

    Fujino, T.; Lewis, J.; Chen, B. Y.; Sievers, Q.; Cai, W.; Yoo, S.; Mathew, S.; Souness, S.; Burns, E. R.; Um, J. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide and dexamethasone (VRd) versus alone in patients with transplant-ineligible newly diagnosed multiple myeloma or for whom transplant is not planned as initial therapy: Analysis of minimal residual disease in the CEPHEUS trial
    Meeting Abstract

    Zweegman, S.; Facon, T.; Hungria, V.; Bahlis, N. J.; Venner, C. P.; Braunstein, M.; Pour, L.; Tutusaus, J. M.; Basu, S.; Cohen, Y. C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mis-splicing derived neoantigens and cognate T cell receptors in splicing factor mutant myeloid neoplasms
    Meeting Abstract

    Kim, W. J.; Crosse, E. I.; De Neef, E.; Etxeberria, I.; Sabio, E.; Wang, E.; Bewersdorf, J. P.; Lu, S. X.; Belleville, A.; Fox, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Preliminary safety and biomarker results of the NLRP3 inflammasome inhibitor DFV890 in adult patients with myeloid diseases: A phase 1b study
    Meeting Abstract

    Garcia-Manero, G.; Abaza, Y.; Greenberg, P. L.; Haque, T.; Kennedy, K. V.; Della Porta, M. G.; Ooi, M. G.; Stahl, M.; Xie, Z.; Mangaonkar, A. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term follow up of a prospective pilot study of an α/β T-lymphocyte depleted graft conditioned with a reduced intensity regimen in patients with hematologic malignancies
    Meeting Abstract

    Hughes, C. F. M.; Lin, R. J.; Devlin, S. M.; Shaffer, B. C.; Jakubowski, A. A.; Talla, V.; Saldia, A.; Gyurkocza, B.; Papadopoulos, E. B.; Giralt, S. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Fixed-duration epcoritamab + R(2) drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the EPCORE NHL-2 trial
    Meeting Abstract

    Falchi, L.; Balari, A. S.; Leppä, S.; Vermaat, J. S. P.; Nijland, M.; Christensen, J. H.; de Vos, S.; Holte, H.; Merryman, R. W.; Lugtenburg, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Non-driver genomic alterations and venous thromboembolism in myeloproliferative neoplasms
    Meeting Abstract

    Ajufo, H.; Leader, A.; Derkach, A.; Chrysafi, P.; Singh, R.; Rampal, R.; Mantha, S.; Zwicker, J. I.
    Blood (2024)

    Fulltext@MSK | Save